The world apheresis association registry, 2023 update
Language English Country England, Great Britain Media print-electronic
Document type Journal Article, Review
PubMed
37827962
DOI
10.1016/j.transci.2023.103831
PII: S1473-0502(23)00246-X
Knihovny.cz E-resources
- Keywords
- Adverse events, Apheresis, Indications, Procedures, Register,
- MeSH
- Tissue Donors MeSH
- Child MeSH
- Adult MeSH
- Infant MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Young Adult MeSH
- Infant, Newborn MeSH
- Plasmapheresis MeSH
- Child, Preschool MeSH
- Registries MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Blood Component Removal * methods MeSH
- Plasma Exchange adverse effects MeSH
- Check Tag
- Child MeSH
- Adult MeSH
- Infant MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Young Adult MeSH
- Male MeSH
- Infant, Newborn MeSH
- Child, Preschool MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
The WAA apheresis registry contains data on more than 140,000 apheresis procedures conducted in 12 different countries. The aim is to give an update of indications, type and number of procedures and adverse events (AEs). MATERIAL AND METHODS: The WAA-registry is used for registration of apheresis procedures and is free of charge. The responsible person for a center can apply at the site www.waa-registry.org RESULTS: Data includes reported AEs from 2012 and various procedures and diagnoses during the years 2018-2022; the latter in total from 27 centers registered a total of 9500 patients (41% women) that began therapeutic apheresis (TA) during the period. A total of 58,355 apheresis procedures were performed. The mean age was 50 years (range 0-94). The most common apheresis procedure was stem cell collection for which multiple myeloma was the most frequent diagnosis (51%). Donor cell collection was done in 14% and plasma exchange (PEX) in 28% of patients; In relation to all performed procedures PEX, using a centrifuge (35%) and LDL-apheresis (20%) were the most common. The main indication for PEX was TTP (17%). Peripheral veins were used in 56% as the vascular access. The preferred anticoagulant was ACD. AEs occurred in 2.7% of all procedures and were mostly mild (1%) and moderate 1.5% (needed supportive medication) and, only rarely, severe (0.15%). CONCLUSION: The data showed a wide range of indications and variability in apheresis procedures with low AE frequency.
4 Internal Hematological Klinik Fakultni Nemocnice Hradec Králové Czech Republic
Apheresis Center University Hospital Orebro Sweden
Apheresis Department Institute of Hematology and Blood Transfusion Prague Czech Republic
Blood Centre University Hospital Ostrava Ostrava Czech Republic
Dep of Immunology and Transfusion Medicine Akershus University Hospital Lorenskog Norway
Department Haematology University Hospital Ankara Turkey
Department of Clinical Microbiology Division of Clinical Immunology Umeå University Umeå Sweden
Department of Nephrology University Hospital Uppsala Sweden
Nephrocare Rostock GmbH Rostock Germany
Public Health and Clinical Medicine Umeå University Umeå Sweden
South African National Blood Service Johannesburg South Africa
St Anna Kinderspital University Hospital Vienna Austria
Therapeutic apheresis unit Vilnius university hospital Santariskiu clinics Vilnius Lithuania
References provided by Crossref.org